Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Tourmaline Bio's TOUR-006?
TOUR-006 is a monoclonal antibody commercialized by Tourmaline Bio, with a leading Phase II program in Graves' Ophthalmopathy. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Tourmaline Bio's TOUR-006?
TOUR-006 is a monoclonal antibody commercialized by Tourmaline Bio, with a leading Phase II program in Graves' Ophthalmopathy. According to...